ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2143

Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies

Takayuki Kishi1, Jonathan Chipman1, Maryalice Stetler-Stevenson2, Khanh Nghiem3, Melvina Evereklian1, Margaret E. Rick3, Frederick W Miller1 and Lisa G Rider1, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 2Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD, 3Coagulation Laboratory, Clinical Center, National Institutes of Health, Bethesda, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, endothelial cells, inflammatory myositis, juvenile dermatomyositis and nailfold capillaroscopy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The idiopathic inflammatory myopathies (IIM) are systemic autoimmune diseases with chronic muscle inflammation and microvasculopathy of muscle and skin capillaries. Circulating endothelial cells (CECs), von Willebrand Factor antigen (vWF), P-selectin, and thrombomodulin are released from damaged endothelium. Loss of function of endothelial progenitor cells (EPCs) has been associated with poor vascular outcomes in other autoimmune diseases. These endothelial markers may be part of the pathogenic changes of IIM and we hypothesized they may be indicators of disease activity.

Methods: We assessed endothelial biomarkers in 24 probable or definite IIM patients (20 juvenile dermatomyositis (DM), 2 adult DM, 1 each with juvenile and adult polymyositis) with a median age of 12.6 yrs [IQR 9.8-16.4] and 67% female, and in 29 healthy controls with similar ages and genders. CECs and EPCs in peripheral blood were quantitated by flow cytometry. EPC markers included CD34+/133+, KDR+/133+, and CXCR4+/133+. Plasma vWF antigen (Ag) was measured in an immunoassay, vWF activity in a Ristocetin cofactor assay, and Factor VIII (FVIII) in a one-stage clotting assay based on activated partial thromboplastin time. Thrombomodulin and P-selectin were measured by ELISA. IMACS and PRINTO myositis disease activity and damage measures were assessed and periungual nailfold capillary (NFC) morphology and density were quantified using digital photographs in IIM patients. Group differences were evaluated by Wilcoxon-rank sum test, and Spearman’s rank correlations assessed relationships between variables.

Results: Among endothelial markers, CECs (median 0.89 vs. 0.20 cells/uL, p<0.001), vWF Ag (median 159 vs. 94 IU/mL, p<0.001), vWF activity (median 150 vs. 118 IU/dL, p=0.018), FVIII (median 187 vs. 141 IU/dL, p=0.004), and thrombomodulin (median 7.68 vs. 2.08 ng/mL, p=0.020), but not EPC subsets or P-selectin, were elevated in IIM patients vs. healthy controls. vWF measures correlated with each other and FVIII (rs 0.74-0.83, p=<0.001). CECs correlated with pulmonary and extramuscular activity, and Disease Activity Scores (DAS) (rs 0.47-0.65, p≤0.022), and inversely with NFC density (rs -0.43, p=0.052). vWF Ag correlated with physician global activity, extramuscular activity, and the extent of NFC avascularity (rs 0.44-0.51, p≤0.034). KDR+/133+ EPC cells negatively correlated with constitutional and extramuscular activity, total and muscle DAS scores, [C]HAQ, and LDH (rs -0.50 – -0.67, p≤0.043) and positively correlated with CMAS, NFC density and tortuosity (rs 0.50 – 0.80, p≤0039). Thrombomodulin only correlated with gastrointestinal activity (rs 0.48, p=0049). None of the markers correlated with brachial artery flow-mediated dilation, Myositis Damage Index or physician global damage.

Conclusion: Markers of endothelial damage, including CECs, vWF and thrombomodulin, were increased in IIM patients, and correlate with some extramuscular measures of myositis activity, suggesting they may be good biomarkers for myositis phenotypes. EPCs, in contrast, correlate inversely with myositis activity measures, suggesting blood vessel regeneration may be diminished during active disease.


Disclosure: T. Kishi, Cure JM Foundation, 2; J. Chipman, None; M. Stetler-Stevenson, None; K. Nghiem, None; M. Evereklian, None; M. E. Rick, None; F. W. Miller, None; L. G. Rider, None.

To cite this abstract in AMA style:

Kishi T, Chipman J, Stetler-Stevenson M, Nghiem K, Evereklian M, Rick ME, Miller FW, Rider LG. Circulating Endothelial Cells and Endothelial Activation Markers As Disease Activity Measures in Idiopathic Inflammatory Myopathies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/circulating-endothelial-cells-and-endothelial-activation-markers-as-disease-activity-measures-in-idiopathic-inflammatory-myopathies/. Accessed October 1, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/circulating-endothelial-cells-and-endothelial-activation-markers-as-disease-activity-measures-in-idiopathic-inflammatory-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology